Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

113.15
-1.4800-1.29%
Post-market: 112.81-0.3400-0.30%16:15 EDT
Volume:900.88K
Turnover:101.58M
Market Cap:9.41B
PE:-35.23
High:114.50
Open:114.50
Low:110.29
Close:114.63
52wk High:130.05
52wk Low:47.86
Shares:83.15M
Float Shares:64.87M
Volume Ratio:1.40
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.23
PE(LYR):-30.66

Loading ...

Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis

TIPRANKS
·
Aug 06

Kymera Therapeutics, Inc. : Citigroup Raises Target Price to $135 from $120

THOMSON REUTERS
·
Aug 06

Kymera Therapeutics price target raised to $139 from $133 at Barclays

TIPRANKS
·
Aug 06

Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge

Reuters
·
Aug 06

Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment

Reuters
·
Aug 06

Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments

Reuters
·
Aug 06

Editas Medicine Q2 Net Loss Narrows and Beats Estimates

Reuters
·
Aug 06

Kymera Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Kymera Therapeutics Posts Corporate Deck Outlining Push to Develop Oral Targeted Protein Degraders for Immunology

Reuters
·
Aug 05

Kymera Q2 2026 Earnings: Milestone Revenue Narrows Net Loss

TradingKey
·
Aug 05

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Earnings Flash (KYMR) Kymera Therapeutics Posts Q2 Loss $0.62 a Share, vs. FactSet Est of $0.71 Loss

MT Newswires Live
·
Aug 05

Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate

Benzinga Earnings
·
Aug 05

Kymera Therapeutics Q2 EPS USD -0.62

THOMSON REUTERS
·
Aug 05

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

THOMSON REUTERS
·
Aug 05

Kymera Therapeutics (KYMR) Could Be 23% Undervalued On Its New CMO Appointment

Simply Wall St.
·
Aug 02

Kymera Therapeutics Inc : Deutsche Bank Initiates Coverage with Hold Rating; Target Price $120

THOMSON REUTERS
·
Jul 30

Kymera Therapeutics Schedules Quarterly Financial Results Webcast

Reuters
·
Jul 29

Kymera Therapeutics price target raised to $135 from $125 at Guggenheim

TIPRANKS
·
Jul 28

Kymera Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer Terence Rooney

Reuters
·
Jul 28